Limits...
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH - PLoS ONE (2015)

Bottom Line: To determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.Pair-wise meta-analyses and mixed treatment comparisons were conducted to examine the difference in weight change at six months between the glucagon-like peptide-1 receptor agonists and each comparator.This review provides evidence that glucagon-like peptide-1 receptor agonist therapies are associated with weight loss in overweight or obese patients with type 2 diabetes with no difference in weight loss seen between the different types of GLP-1 receptor agonists assessed.

View Article: PubMed Central - PubMed

Affiliation: University of Leicester, Department of Health Sciences, Leicester, United Kingdom.

ABSTRACT

Aims: To determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.

Methods: Electronic searches were conducted for randomised controlled trials that compared a glucagon-like peptide-1 receptor agonist therapy at a clinically relevant dose with a comparator treatment (other type 2 diabetes treatment or placebo) in adults with type 2 diabetes and a mean body mass index ≥ 25 kg/m2. Pair-wise meta-analyses and mixed treatment comparisons were conducted to examine the difference in weight change at six months between the glucagon-like peptide-1 receptor agonists and each comparator.

Results: In the mixed treatment comparison (27 trials), the glucagon-like peptide-1 receptor agonists were the most successful in terms of weight loss; exenatide 2 mg/week: -1.62 kg (95% CrI: -2.95 kg, -0.30 kg), exenatide 20 μg: -1.37 kg (95% CI: -222 kg, -0.52 kg), liraglutide 1.2 mg: -1.01 kg (95%CrI: -2.41 kg, 0.38 kg) and liraglutide 1.8 mg: -1.51 kg (95% CI: -2.67 kg, -0.37 kg) compared with placebo. There were no differences between the GLP-1 receptor agonists in terms of weight loss.

Conclusions: This review provides evidence that glucagon-like peptide-1 receptor agonist therapies are associated with weight loss in overweight or obese patients with type 2 diabetes with no difference in weight loss seen between the different types of GLP-1 receptor agonists assessed.

No MeSH data available.


Related in: MedlinePlus

Network diagram of treatments comparisons in analysis.Numbers represent the number of studies that reported a direct comparison between each pair of treatments. Line thickness is weighted so that a thicker line represents a higher number of direct comparisons.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4487255&req=5

pone.0126769.g002: Network diagram of treatments comparisons in analysis.Numbers represent the number of studies that reported a direct comparison between each pair of treatments. Line thickness is weighted so that a thicker line represents a higher number of direct comparisons.

Mentions: In the 27 trials, 16 different interventions were given, and there were 31 direct comparisons reported between the different interventions (Fig 2). The GLP-1 receptor agonist therapies included were exenatide 20μg daily, exenatide 2mg/week, liraglutide 1.2mg daily and liraglutide 1.8mg daily. Lixisenatide was not included because no eligible studies considering this treatment were identified in the review process. Control interventions included placebo and metformin among others (Fig 2). According to the inclusion criteria, all included trials reported a mean body mass index of > 25kg/m2 (range 25.8kg/m2–35.0kg/m2). The age of participants ranged from 51 years to 60 years. The minimum percentage of females included was 29.7% ranging up to trials where 63% of the participants were female (Table 1).


The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH - PLoS ONE (2015)

Network diagram of treatments comparisons in analysis.Numbers represent the number of studies that reported a direct comparison between each pair of treatments. Line thickness is weighted so that a thicker line represents a higher number of direct comparisons.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4487255&req=5

pone.0126769.g002: Network diagram of treatments comparisons in analysis.Numbers represent the number of studies that reported a direct comparison between each pair of treatments. Line thickness is weighted so that a thicker line represents a higher number of direct comparisons.
Mentions: In the 27 trials, 16 different interventions were given, and there were 31 direct comparisons reported between the different interventions (Fig 2). The GLP-1 receptor agonist therapies included were exenatide 20μg daily, exenatide 2mg/week, liraglutide 1.2mg daily and liraglutide 1.8mg daily. Lixisenatide was not included because no eligible studies considering this treatment were identified in the review process. Control interventions included placebo and metformin among others (Fig 2). According to the inclusion criteria, all included trials reported a mean body mass index of > 25kg/m2 (range 25.8kg/m2–35.0kg/m2). The age of participants ranged from 51 years to 60 years. The minimum percentage of females included was 29.7% ranging up to trials where 63% of the participants were female (Table 1).

Bottom Line: To determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.Pair-wise meta-analyses and mixed treatment comparisons were conducted to examine the difference in weight change at six months between the glucagon-like peptide-1 receptor agonists and each comparator.This review provides evidence that glucagon-like peptide-1 receptor agonist therapies are associated with weight loss in overweight or obese patients with type 2 diabetes with no difference in weight loss seen between the different types of GLP-1 receptor agonists assessed.

View Article: PubMed Central - PubMed

Affiliation: University of Leicester, Department of Health Sciences, Leicester, United Kingdom.

ABSTRACT

Aims: To determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.

Methods: Electronic searches were conducted for randomised controlled trials that compared a glucagon-like peptide-1 receptor agonist therapy at a clinically relevant dose with a comparator treatment (other type 2 diabetes treatment or placebo) in adults with type 2 diabetes and a mean body mass index ≥ 25 kg/m2. Pair-wise meta-analyses and mixed treatment comparisons were conducted to examine the difference in weight change at six months between the glucagon-like peptide-1 receptor agonists and each comparator.

Results: In the mixed treatment comparison (27 trials), the glucagon-like peptide-1 receptor agonists were the most successful in terms of weight loss; exenatide 2 mg/week: -1.62 kg (95% CrI: -2.95 kg, -0.30 kg), exenatide 20 μg: -1.37 kg (95% CI: -222 kg, -0.52 kg), liraglutide 1.2 mg: -1.01 kg (95%CrI: -2.41 kg, 0.38 kg) and liraglutide 1.8 mg: -1.51 kg (95% CI: -2.67 kg, -0.37 kg) compared with placebo. There were no differences between the GLP-1 receptor agonists in terms of weight loss.

Conclusions: This review provides evidence that glucagon-like peptide-1 receptor agonist therapies are associated with weight loss in overweight or obese patients with type 2 diabetes with no difference in weight loss seen between the different types of GLP-1 receptor agonists assessed.

No MeSH data available.


Related in: MedlinePlus